Stay updated on Amivantamab in Esophagogastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.

Latest updates to the Amivantamab in Esophagogastric Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check42 days agoChange DetectedThe web page has been updated to reflect a new version of the study on Amivantamab for esophagogastric cancer, with the principal investigator now listed as Steven Maron, MD, and the revision updated to v2.15.0. Significant details regarding the study's purpose and inclusion criteria have been removed.SummaryDifference34%
- Check49 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check85 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check106 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check114 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Amivantamab in Esophagogastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab in Esophagogastric Cancer Clinical Trial page.